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I.  Abstract 
 
Background: As more Americans attempt to take charge of their health, interest in and usage 
of nutritional supplements has increased among the general population, and even more among 
cancer patients.  However, few studies have accurately measured supplement use among this 
population.  There is little scientific evidence that supplements will reduce the side effects of 
cancer therapy or directly treat the cancer.  In addition, controversy surrounding antioxidants 
and their effect on cancers treated with radiation therapy raises many questions regarding their 
safety and efficacy. 
 
Objective:  To define the nutritional supplement use among women and men undergoing 
radiation therapy for breast and prostate cancers, including amount, frequency, and type of 
supplement use as well the relationship between supplement use and quality of life. 
 
Design:  Fifty-six women and fifty-two men with newly diagnosed breast and prostate cancers 
who chose radiation treatment completed an interview regarding their supplement use and 
completed demographic and quality of life questionnaires prior to the initiation of radiation 
therapy, at completion of radiation therapy, and at follow-up six weeks later.  Supplement 
ingredients and amounts consumed were quantified, and demographic and quality of life data 
was entered into Excel databases.   
 
Results:  The mean age was 53 years for breast cancer patients and 63 years for prostate 
cancer patients.  At the initiation of radiation therapy, 73% (n=41) of women and 63% (n=33) of 
men reported supplement use. A total of 133 different supplement products were consumed 
among women and 113 among men.  Among supplement users, an average of 3.2 supplements 
per woman and 3.4 supplements per man was consumed.  The most common supplement 
consumed in both sexes was a combination multivitamin/multimineral (52% of women, 44% of 
men).  Antioxidants were also prevalent, with 46% of men and women consuming supplements 
containing antioxidant nutrients at the initiation of therapy, excluding those in multivitamin 
products.  For breast cancer patients, indicators of quality of life such as global health status 
increased from initiation of radiation therapy to follow-up six weeks following therapy 
completion, while indicators of physical and functioning and fatigue did not significantly change.  
In the prostate cancer cohort, physical functioning and vitality markers steadily decreased 
throughout the enrollment period, while markers of general health were varied.  The relationship 
of supplement use to quality of life indicators is currently under investigation. 
 
Significance:  This study is one of the most detailed and accurate assessments of supplement 
use among cancer patients undergoing radiation therapy.  Our findings suggest that supplement 
use among women and men newly diagnosed with breast and prostate cancers is more 
common than previously reported for cancer patients, and significantly higher than the general 
population.  Defining dietary supplement use of these cohorts will help us design randomized 
clinical trials to investigate the effects of supplements on cancer treatment with radiation 
therapy. 
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II.  Introduction 
 
 As more Americans attempt to take charge of their health, interest in and usage of 
nutritional supplements has increased among the general population.  Recent cross-sectional 
studies including the Third National Health and Nutrition Examination Survey (NHANES III) 
estimate that approximately 52% of the U.S. population takes a vitamin, mineral, or other dietary 
supplement (CDC).  The prevalence of nutritional supplement use among patients with a history 
of cancer has been reported to be even higher (Miller, et al. 2008).  Accurate quantification of 
nutritional supplement use is very difficult.  Many patients do not report use of supplements to 
their medical caregivers and reviewing a medical chart notoriously underestimates supplement 
use.  A study by Hensrud et al. in 1999 found that only 30.5% of patients reported supplement 
use during a routine physical exam on their medical forms.  Additionally, studies which rely on 
self-report are frequently inaccurate as patients often cannot recall the type of supplement taken 
and rarely can provide information regarding the dose of supplement components.  Although 
information marketed towards consumers advertises the health benefits of supplements, little is 
known about their bioavailability, mechanisms of action within the body, interactions with one 
another, and overall safety and efficacy. 
 One area of particular controversy concerns the role of supplements, particularly those 
in the category called “antioxidants”, during radiation therapy for cancer.  It is well known that 
ionizing radiation induces free-radical formation and that this is one mechanism mediating the 
therapeutic action of radiotherapy.  Thus, two opposing hypotheses have emerged.  One 
proposes that increased antioxidant supplementation will prevent the side-effects of radiation.  
The opposing hypothesis suggests that increasing antioxidant supplements in a cancer will 
reduce the ability of radiation to treat the cancer.  These opposing concepts have not been 
adequately tested in humans and evidence based guidance for those undergoing radiotherapy 
is essentially nonexistent.   
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 Our long-term goal is to address this issue.  In order to proceed with future studies in this 
field it will first be necessary to accurately document the current prevalence of supplement use, 
the types of supplements consumed, and the doses of various components consumed during 
cancer radiotherapy for specific cancer types.  Accurately quantifying nutritional supplement use 
among cancer patients is essential to beginning to understand the effects of supplements on 
radiation therapy.    
 
Supplement Usage in the General Population: 
 
 Nutritional supplement use among the general population has been consistently 
increasing.  The Slone Survey conducted by Kaufman et al., in the late 1990’s found that 40% of 
the 2590 participants had reported taking a vitamin or mineral in the preceding week, and 14% 
reported taking at least one herbal supplement.  Percentages can be assumed to be even 
higher with the advent of the 21st century, as evidenced by a national survey indicating an 
increase in use of complementary and alternative medicine from 43% in 1997 to 62% in 2002 
(Bardia et al. 2007).  It is clear, however, that many consumers are unaware of the effects and 
safety of many of these supplements.  Greger (2001) states that consumers are beginning to 
take charge of their health, but that characteristics of supplement use predict less than 30% of 
diet-related behaviors.  This is important because it implies that consumers may be taking 
nutritional supplements while being unaware of their diets.  In addition, traditional medicine 
practitioners often lack information on supplements, and it is difficult to determine which 
agencies are most qualified to disseminate information to the public (Greger, 2001). 
 It is interesting to note the reasons consumers take nutritional supplements, and even 
more surprising to find that some do not take certain supplements for their evidence-based 
indications.  In a study conducted by the 2002 National Health Interview Survey, only 55% of 
participants used herbal supplements consistent with their indications (Bardia et al. 2007).  It is 
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therefore important to understand the need to educate supplement users about the indications 
and contraindications for specific vitamins, minerals, and herbal supplements.  Some general 
reasons that consumers have stated for taking vitamins and minerals are for general health, or 
as a supplement to the diet, while herbal medications are consumed most commonly for general 
health, arthritis, and memory improvement (Kaufman et al. 2002).  However, several other 
factors can determine the use, frequency and duration of supplement use.   
 Many studies and surveys have illustrated characteristics of consumers that are more 
likely to take nutritional supplements.  In general, supplement users are frequently older, 
Caucasian, and females (Greger, 2001).  In addition, those consumers who are educated 
beyond high school or have a higher income are more apt to take supplements than those less 
educated or less wealthy.  Positive lifestyle factors such as abstinence from smoking and 
excessive alcohol intake, as well as those who exercise regularly, further prove to be indicators 
of supplement use (Greger, 2001).  A mailed questionnaire study from 2000-2002 reported that 
persons who ate a low fat diet, consumed more fruits and vegetables, and were screened for 
cancer were more likely to take herbal or specialty supplements (Gunther, et al. 2004).  In 
general, trends show that consumers who are more educated, have a higher socioeconomic 
status, are concerned about their health, diet, and physical well-being are more likely to use 
supplements. 
   
Supplement Usage among Cancer Patients: 
 
 Recent studies have reported not only an increase in supplement use among the 
general population, but also among cancer patients.  In 2001, the California Health Interview 
Survey found that supplement use was higher among participants that reported a history of 
cancer, a noncancer chronic condition, or both (Miller et al. 2008).  Interestingly, four of the 
seven commonly consumed vitamins were antioxidants, which have received increased 
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attention for cancer prevention.  Another study from a colorectal chemoprevention trial found 
that 55% of patients with a history of colorectal carcinoma used an average of 2.6 supplements 
each (Sandler, et al. 2001).  It is important to consider not only whether this cohort is taking 
supplements in general but also how many are consumed simultaneously.  
 The term complementary and alternative medicine (or CAM) is often used 
interchangeably with the term nutrient supplement.  However, CAM, as defined by the National 
Institutes of Health, encompasses much more than simply nutritional supplements.  CAM can 
include diet, mind-body techniques, folk remedies, manual healing methods, and vitamin, 
mineral, and herbal treatments (Bernstein, 2001).  Cancer patients and proponents claim that 
various CAM treatments may help to eliminate the side effects of chemotherapy (Bernstein, 
2001).  Some patients even abandon evidence-based therapies in favor of untested CAM 
cancer treatments.   
 Although supplement use is common among cancer patients and survivors, it has been 
reported that adults diagnosed with cancer may also make additional lifestyle changes in diet 
and physical activity.  A cancer diagnosis often may cause psychological distress that motivates 
the individual to begin health promoting activities and to reduce risk (Patterson et al. 2003).  In 
addition, cancer patients that feel a greater sense of personal control will be more motivated to 
change their lifestyle, and therefore may be more likely to take nutritional supplements.  A 
population-based telephone survey of breast, prostate, and colorectal patients revealed that two 
thirds of patients made at least one behavior change in the year after their cancer diagnosis, 
and that 50% started taking new dietary supplements (Patterson et al. 2003).  This data raises 
the significant question of whether supplements are used by cancer patients as a coping 
mechanism or as an actual health improvement strategy. 
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Federal Regulation of the Dietary Supplement Industry: 
 
The 1994 Dietary Supplement, Health and Education Act (DSHEA) significantly changed 
the way supplements were regulated in the United States.  Prior to its passage, the Food and 
Drug Administration regarded dietary supplements as foods, and all ingredients were subject to 
safety evaluation.  However, the passage of DSHEA meant that manufacturing, marketing, and 
the health claims of supplements were no longer monitored and regulated based upon scientific 
rigor and that consumers could no longer assume safety, purity or efficacy.  In other words, 
products were assumed to be safe unless the Food and Drug Administration could prove 
otherwise (JAMA, 2002).  In addition, Congress expanded the definition of a dietary supplement 
to include not only essential nutrients such as vitamins, minerals, and proteins, but also fish oils, 
garlic, enzymes, and other forms of supplementation (FDA, 1995).  Many cancer patients 
consume supplements with the belief that these supplements will reduce the side effects of 
cancer therapy, directly treat the cancer, or reduce the risk of cancer recurrence.   However, 
there is very little scientific evidence to support these claims.  Indeed, it is possible that some 
commonly consumed dietary supplements may actually be harmful to cancer patients.  Thus, 
cancer patients are often unable to obtain scientifically-supported guidance to help them make 
informed decisions about the use of nutritional supplements. 
 
Interactions between Nutrient Supplements and Radiation Therapy:  
 
 One of the most controversial issues regarding supplement usage in cancer patients is 
the use of antioxidants while undergoing radiation therapy.  While antioxidants may decrease 
oxidative stress and potentially play a role in aging and disease prevention, there are also 
studies which claim they may interfere with the body’s defense mechanisms that rid the body of 
damaged cells, such as those involved in cancer development.  Radiation therapy as a 
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treatment for cancer involves direct ionization of DNA and produces free radicals in the tissue, 
with the ultimate goal of increasing DNA damage in tumor cells and altering cell homeostasis to 
increase apoptosis of cancerous cells (Bjelakovic, 2007).  Conversely, antioxidants counteract 
free radicals, prevent tissue damage, and repair cell membranes by affecting processes such as 
cell proliferation, apoptosis, and angiogenesis (Lawenda et al. 2008).  Furthermore, the 
bioavailability and mechanisms of action of antioxidants are unknown and often synthetic and 
factory-processed forms cannot be proven safe.  It is clear that these two processes are in 
direct conflict with each other and that use of antioxidants during radiation therapy must be 
more carefully researched. 
 Despite concern over this issue, there are still arguments for the use of antioxidants 
during radiotherapy.  Many claim that antioxidant supplementation can enhance the benefits of 
treatment by inhibiting the growth of tumor cells.  Some argue that use of antioxidants may also 
alleviate side effects of conventional therapies by reducing toxicities, as well as improving 
general health and well-being (Ladas et al. 2004).  Conversely, those who discourage 
antioxidant supplementation during radiotherapy believe it will interfere with the efficacy of 
treatment by scavenging the free radicals produced by the radiation and by repairing damage to 
the tumor cells the radiation is attempting to destroy.  A study by Bairati is the most important 
randomized clinical trial to date involving use of antioxidant vitamins in head and neck cancer 
patients.  Results found that the severity of negative side effects of radiation was reduced, but 
that overall improvement in quality of life was unchanged with antioxidant supplementation 
(Bairati et al. 2005).  In addition, results illustrated that the antioxidants actually caused adverse 
effects, especially when a-tocopherol and b-carotene were administered together, and that the 
rate of local recurrence of the cancer was 56% higher among the supplemented patients than in 
the placebo group (Bairati et al. 2005).  This study and others confirm the need for greater 
research into trends of antioxidant usage among cancer patients and effects of supplementation 
on the effectiveness of conventional cancer treatments. 
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 The objective of this study is therefore to define the nutritional supplement use among 
women and men undergoing radiation therapy for breast and prostate cancers, including 
amount, frequency, and type of supplement use as well the relationship between supplement 
use and quality of life. 
 
III.  Subjects and Methods: 
  
 Design:  Each enrolled subject was interviewed prior to their first radiation therapy 
treatment for cancer.  The visit consisted of screening the subject for eligibility, obtaining 
consent, and describing the study.  Enrolled subjects were given demographic and quality of life 
questionnaires to complete and return to their next appointment, and were instructed to bring 
containers and labels of all consumed supplements.  Information regarding type of supplement, 
duration of use, and frequency of use was carefully recorded.  Subjects were seen again at the  
completion of radiation therapy and at the follow-up visit six weeks later in which they were 
administered the same demographic and quality of life questionnaires and noted any differences 
in supplement consumption from the initiation of radiation therapy (Figure 1). 
 
                    
Simulation 
Visit/ 
Enroll 
subjects 
Interview 
#1 
Interview 
#2 
Interview 
#3 
Start of Radiation
Therapy 
End of Radiation
Therapy 
Radiation Follow 
Up Visit 
Brachytherapy Clinical Visit Clinical Visit 
Figure 1.  Study Design. 
0     1            5             9               11   
Week 
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Recruitment:  Patients were recruited from a pool of prostate and breast cancer patients 
enrolled at the James Cancer Hospital and Solove Research Institute.  Men had chosen 
external beam irradiation or brachytherapy as treatment for their prostate cancer, and women 
had chosen external beam irradiation for their breast cancer.  There were no age restrictions for 
the study, but subjects who could not independently consent to participation were not included.  
Patients with metastatic cancer were not enrolled.  Fifty-six women and fifty-two men were 
recruited to the study and most completed the three time point interview process.   
 
Data procurement and management: Supplement containers were examined and dosing 
was discussed with each patient to document frequency, duration, and amount of product 
consumed.   Labels were photocopied and components of supplements were entered into an 
Excel database.  When necessary, content of supplements was verified using company 
websites.  Data was also procured through a questionnaire incorporating demographics and a 
second questionnaire which assessed quality of life.  A file for each patient was created and 
included consent forms, all completed questionnaires, and all photocopied supplement labels.   
 
IV.  Statistics:   
 
Demographic data, quality of life data, and supplement use data were entered into three 
different Excel databases and analyzed using descriptive analysis.  Milligram and microgram 
amounts of each nutrient were calculated and all information was stored in a separate Excel 
database.  Descriptive statistics were used to determine demographic characteristics, changes 
in quality of life markers from initiation of radiation therapy to follow up, and possible 
relationships between supplement use and quality of life.  In addition, Excel was used to create 
graphs illustrating number of supplements consumed among supplement users as well as 
categories of dietary supplements consumed.  
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V.  Results: 
 
Demographic Data: 
 
 Refer to Appendix A for the brief demographic questionnaire each patient was asked to 
complete.  As indicated in Table 1, fifty-six breast cancer patients were enrolled in the study, 
with a mean age of 53 years and mean of 4.7 months since diagnosis.  The mean body mass 
index (BMI) was 27.2.  The majority of women were Caucasian (80%), on paid employment 
status (70%), and married (63%).  Seventy-three percent of women completed college or 
graduate school.  Alcohol use was prominent among the cohort, with 55% of women reporting 
alcohol consumption, while only 11% reported smoking. 
 Demographic characteristics for prostate cancer patients are shown in Table 2.  Fifty-two 
prostate cancer patients participated in the study with a mean age of 63 years and mean of 4.0 
months since diagnosis.  The mean body mass index (BMI) of the men was 28.2.  A majority of 
the men were Caucasian (79%) and married (86%).  Education level and employment status 
was relatively spread out, with 39% of men finishing high school, 29% finishing college, 50% 
retired, and 41% on paid employment status.  Alcohol use was more prominent among men 
than cigarette smoking, with 52% reporting alcohol use and 10% reporting smoking. 
 
Quality of Life Data: 
 
 To assess markers of quality of life among the cohort of breast cancer patients, this 
study used the 53-item EORTC Quality of Life Questionnaire-C30 and the EORTC QLQ-BR23 
breast cancer supplementary module (Appendix B).  Three scales were used to assess quality 
of life at initiation of radiation therapy, at completion of therapy, and at follow-up six weeks later.   
 
 12
Table 1.  Demographic characteristics, breast cancer patients. 
 
   Mean (±SD) 
 
Age (years)  52.7 (±10.6) 
Height (inches) 64.6 (±2.8) 
Weight (pounds) 164.2 (±41.3) 
BMI (kg/m2)  27.2 (±7.6) 
Months since Dx 4.7 (±2.4) 
 
   N (%) 
 
Race:  (n=56)    
Caucasian  45 (80.4) 
African American 10 (17.9) 
Hispanic  0 (0.0) 
Other   1 (1.8) 
 
Education:  (n=54) 
Some High School 2 (3.6) 
High School  11 (19.6) 
College   24 (42.9) 
Graduate School 17 (30.4) 
 
Employment:  (n=55) 
Paid   39 (70.0) 
Retired   3 (5.4) 
Unemployed  7 (12.5) 
Other   6 (10.7) 
N (%) 
 
Income:  (n=51) 
<$20,000  6 (10.7) 
$20,000-$39,999 16 (28.6) 
$40,000-$59,999 10 (17.9) 
$60,000-$99,999 11 (19.6) 
>$100,000  8 (14.3) 
 
Marital Status:  (n=55) 
Single   7 (12.5) 
Married   35 (62.5) 
Widowed  3 (5.4) 
Divorced/Separated 10 (17.9) 
 
Smoking:  (n=55) 
Smoker   6 (10.7) 
Nonsmoker   49 (87.5) 
 
Alcohol Use: (n=54) 
Yes   31 (55.4) 
No   23 (41.1) 
 
Table 2.  Demographic characteristics, prostate cancer patients. 
 
   Mean (±SD) 
 
Age (years)  62.8 (±7.7) 
Height (inches) 70.4 (±2.9) 
Weight (pounds) 198.4 (±32.7) 
BMI (kg/m2)  28.2 (±4.4) 
Months since Dx 4.0 (±4.3) 
 
   N (%) 
 
Race:  (n=52)    
Caucasian  41 (78.9) 
African American 8 (15.4) 
Hispanic  0 (0.0) 
Other   3 (5.8) 
 
Education:  (n=52) 
Some High School 6 (11.5) 
High School  20 (38.5) 
College   15 (28.9) 
Graduate School 11 (21.2) 
 
Employment:  (n=51) 
Paid   21 (41.2) 
Retired   26 (50.0) 
Unemployed  1 (2.0) 
Other   3 (5.9) 
   N (%) 
 
Income:  (n=44) 
<$20,000  7 (15.9) 
$20,000-$39,999 12 (27.3) 
$40,000-$59,999 12 (27.3) 
$60,000-$99,999 6 (13.6) 
>$100,000  7 (15.9) 
 
Marital Status:  (n=51) 
Single   3 (5.9) 
Married   44 (86.3) 
Widowed  0 (0.0) 
Divorced/Separated 4 (7.8) 
 
Smoking:  (n=52) 
Smoker   5 (9.6) 
Nonsmoker   47 (90.4) 
 
Alcohol Use: (n=50) 
Yes   26 (52.0) 
No   24 (48.0) 
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Global health status was based on women’s perceived ratings of overall health and quality of 
life, physical functioning related to ability to perform everyday and strenuous activities, and 
fatigue was based on feelings of weakness and need to rest.  Each scale was converted from a 
raw score to a score between 0 and 100.  For global health status and physical functioning, a 
higher score indicated higher levels of quality of life and physical functioning, while a higher 
fatigue score indicated greater weakness and need to rest. 
 These markers were assessed at each of the three time points and divided into four 
quadrants: 0-25, 26-50, 51-75, and 76-100, to more easily determine changes throughout the 
enrollment period.  Global health status greatly increased among women from initiation of 
radiation therapy to follow-up, with only 36% of women indicating a score between 76-100 at 
time point 1, but 63% of women indicating this score at time point 3 (Figure 2).  Physical 
functioning, indicated in Figure 3, did not change greatly throughout the enrollment period, with 
a majority of women indicating a score of 76-100 at all three time periods (82%, 78%, and 90% 
of women, respectively).  Changes in fatigue were seen throughout the period, although not as 
directly as in global health status (Figure 4).  Fifty-four percent of women reported low levels of 
fatigue at initiation of radiation therapy, while 79% reported the same at follow-up six weeks 
after completion of therapy.  Less than 10% of women reported high levels of fatigue, 
corresponding to a score of 51-100, at any given time point. 
 Quality of life was assessed for the prostate cancer patients using the RAND 36-Item 
Health Survey v2 (SF-36 v2) and UCLA Prostate Cancer Index questionnaire (Appendix C).  
Once again, three markers were used to assess quality of life at initiation of radiation therapy, 
completion of radiation therapy, and follow-up six weeks following therapy completion.  General 
health was based on the patient’s view of their personal health, their health related to others 
they know, and expectations of health changes in their future.  Physical functioning related to 
ability to perform vigorous, moderate, and everyday activities, and vitality was based on the 
patient’s energy level and feelings of weakness or fatigue.  Raw scores were scaled to a final 
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score between 0 and 100, with a higher score indicating a higher quality of life.  Each of the 
three markers were divided into the same four quadrants as with the breast cancer data to more 
easily determine changes in quality of life throughout the enrollment period. 
 There was a clear decrease in physical functioning among prostate cancer patients from 
initiation of radiation therapy to follow-up (Figure 5).  Those reporting in the highest quadrant of 
scores, between 75 and 100, fell from 71% to 60% to 46% of men among the respective time 
points.  Simultaneously, those reporting in the lowest quadrant between 0 and 25 rose from 8% 
to 27% to 39% of men.  Vitality scores also decreased, especially between initiation and 
completion of radiation therapy, as seen in Figure 6.  Thirty-nine percent of men reported high 
vitality scores at initiation of radiation therapy, which dropped to only 21% of men at completion 
of therapy.  Finally, changes in general health throughout the enrollment period are shown in 
Figure 7.  This marker was more varied than in the case of physical functioning and vitality; 
however, more men felt negatively, reporting scores between 0 and 25, about their general 
health at follow-up than at the initiation of radiation therapy.  There was a slight increase, 
though, from 33% to 36%, in men reporting the highest scores between 75 and 100 from 
initiation of therapy to completion. 
 Relationship of supplement use to quality of life indicators were unable to be determined 
by the extent of this study and are currently under investigation. 
Figure 2. Global Health Status Among Breast Cancer Patients
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Figure 3. Physical Functioning Among Breast Cancer Patients
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Figure 4. Fatigue Among Breast Cancer Patients
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Figure 5.  Physical Functioning Among Prostate Cancer 
Patients
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 Figure 6.  Vitality Among Prostate Cancer Patients
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Figure 7.  General Health Among Prostate Cancer Patients
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Supplement Use Data: 
 
Breast Cancer Patients: 
 
At the initiation of radiation therapy, 73% (n=41) of women reported supplement use 
(Figure 8).  A total of 133 different supplement products were consumed and an average of 3.2 
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supplements per woman were consumed among supplement users.  Number of supplements 
consumed among breast cancer patients is seen in Figure 9.  Fourteen women reported 
consumption of only one supplement, followed by 9 women reporting use of two supplements 
and 7 women reporting use of three supplements.  The largest number of supplements 
consumed was 16, reported by one patient. 
The most common supplement consumed was a combination multivitamin or 
multimineral (52%), followed by vitamin D and/or calcium products (32%), as shown in Figure 
10.  The two major antioxidant nutrients, vitamin C and vitamin E, were consumed by 15 women 
and 9 women, respectively.  Forty-six percent of women reported consuming supplements 
containing these two antioxidant vitamins at the initiation of therapy, excluding those found in a 
multivitamin supplement.  Herbal supplements, coenzyme Q10, and anti-arthritic supplements 
glucosamine and chondroitin were also reported among several women.  Fourteen supplements 
which were consumed by only one woman were separated into a category noted as “other” 
(Table 3). 
Figure 8. Supplement Use At Initiation Of Radiation Therapy: 
Breast Cancer Patients
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Figure 9. Number of Supplements Taken 
Among Supplement Users:  Breast Cancer Patients
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Figure 10.  Categories of Dietary Supplements Consumed:  Breast 
Cancer Patients
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Table 3.  Supplements classified as “other” among  
breast cancer patients. 
 
Conjugated linoleic acid Mushroom Immune Def. 
Wobenzyme   Protein bar 
Sun Chlorella   Food Enzymes 
Cranberry Extract  Trigger Immune 
Bromelain   Whey protein 
Cell Forte   Blood Build 
Pancreatin   Juice Plus 
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Prostate Cancer Patients: 
 
 Among 52 prostate cancer patients enrolled in the study, 63% (n=33) reported 
consuming dietary supplements at the initiation of radiation therapy (Figure 11).  A total of 113 
different supplement products were consumed, and an average of 3.42 supplements were 
consumed among supplement users.  Figure 12 illustrates the number of supplements taken 
among prostate cancer patients at initiation of radiation therapy.  Twenty-five men reported 
taking between 1 and 3 supplements, with the most frequent being only a single supplement.  
One patient reported consuming 19 different supplement products. 
 As shown in Figure 13, the most common type of product consumed was a multivitamin 
or multimineral (44%), followed by single antioxidant nutrients vitamin E (27%) and vitamin C 
(19%), and vitamin D and/or calcium products (19%).  Forty-six percent of men were consuming 
single antioxidant nutrient supplements at the initiation of radiation therapy.  Herbal 
supplements were also fairly common among this cohort of patients, especially saw palmetto 
and garlic products, and were reported among 8 patients.  Several unique supplements were 
consumed by this cohort and are noted as “other” in Table 4.     
Figure 11.  Supplement Use At Initiation Of Radiation Therapy: Prostate Patients
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Figure 12.  Number of Supplements Taken Among Supplement Users: Prostate Patients
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Figure 13.  Categories of Dietary Supplements Consumed By 
Prostate Cancer Patients
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Table 4.  Supplements classified as “other” among 
prostate cancer patients. 
 
Juice Plus  Chlorella Super 
Optiflora  Alpha Lipoin Acid 
Flaxseed  Fiber Plan 
Lysine   Colorad 
Shark cartilage Soy isoflavones 
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VI.  Discussion 
 
 At initiation of radiation therapy, 73% of breast cancer patients and 63% of prostate 
cancer patients reported consumption of at least one dietary supplement.  These percentages 
are significantly higher than averages for the general population, which have been reported at 
approximately 52% (Radimer, 2004).  Furthermore, these percentages are higher than 
previously reported for cancer patients.  In keeping with published literature, this study found 
that breast cancer patients and women are likely to take more supplements than individuals with 
other cancers or males (Patterson, 2003).  In both cohorts, combination multivitamins and 
multiminerals were most common, but several other nutrients and supplement products were 
prevalent, specifically vitamin D and calcium products, vitamin C, vitamin E, and herbal 
products.  An important finding of this study was that a significant number of breast and prostate 
cancer patients were consuming supplements with antioxidant nutrients at therapy initiation, 
which are now being investigated as having possible negative effects on radiation therapy.  It is 
imperative that these patients become aware of the dosages of antioxidants they are consuming 
and the possible effects these products may have on their cancer treatment. 
 In addition to the findings involving supplement use among these populations, quality of 
life changed greatly between initiation of radiation and follow-up six weeks later.  For breast 
cancer patients, global health status increased steadily throughout the period, while physical 
functioning and fatigue markers did not greatly change.  These patients likely reported feelings 
of higher quality of life simply due to undergoing treatment and subsequent feelings of 
empowerment of their disease.  Among prostate cancer patients, all three markers of quality of 
life assessed decreased from the beginning to the end of the enrollment period.  This is to be 
expected, as radiation for prostate cancer often produces more severe side effects than in 
breast cancer.  Moreover, greater difficulties in sexual function in men resulting from treatment 
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may cause the patients to overestimate feelings of ill health or low quality of life.  In general, 
however, it is clear that treatment with radiotherapy affects several aspects of quality of life. 
 This study has several strengths and limitations.  The most important strength of the 
study is its detail and accuracy in obtaining data about supplement use.  Unlike many past 
studies, this analysis did not rely on self-report in that patients physically brought supplement 
bottles to their appointments rather than recall their names, dosages, and ingredients.  This 
method will allow for much easier and more accurate quantification of data for future 
interventions in this population.  However, it is important to realize that there are several 
confounding factors that may have contributed to these results.  Health conditions other than 
cancer, possible chemotherapy or surgery before radiation, mental conditions, and personal 
beliefs likely played in a role in each patient’s decision to begin or stop taking supplements.  
Quality of life data was rather subjective and changes in questionnaire answers could have 
been attributed to factors other than the radiation treatment.  Finally, it is necessary to recognize 
that this study used a small, relatively homogeneous cohort of patients in an academic setting.  
The majority of participants were Caucasian, retired or employed with a steady income, and 
relatively well-educated, which are all indicators of increased supplement use.  Therefore, the 
results and conclusions drawn may not be generalized to all breast and prostate cancer 
patients.  More research is necessary to control for these factors and to more specifically 
quantify supplement use among a larger cohort of cancer patients. 
 
VII.  Significance 
 
 Completion of this project has set a foundation for future studies in the field of dietary 
supplements and cancer.  Defining the supplement use of these two populations is a necessary 
step to begin a randomized clinical trial to investigate the effects of supplements on radiation 
therapy.  Specifically, an ethical clinical trial should be designed to examine the effect of 
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antioxidant supplements on radiation, since a large proportion of these cohorts were consuming 
supplements with antioxidant nutrients at initiation of radiation therapy.  Studies investigating the 
relationship between supplement use and quality of life may also be beneficial.  In addition, 
understanding the trends in supplement usage among breast and prostate cancer patients will 
lead to more tailored educational interventions to both consumers and health professionals.  
Finally, future studies can use the existing data from the supplements taken among these 
populations to determine specific nutrient toxicities and deficiencies that may positively or 
negatively affect their therapy or cancer diagnosis. 
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 This brief questionnaire should take no more than 5 minutes to complete. You can choose to fill it in now and return 
it to the study coordinator immediately or return the questionnaire the next day before your scheduled radiation 
therapy.  
 
Cancer Site:    Prostate  
     Breast  
 
Date of Cancer Diagnosis: __________________ (month/ year) 
 
Age:     ≤ 30 yr 
     31- 40 yr 
41- 50 yr 
51- 60 yr 
61- 70 yr 
     ≥70 yr 
 
Gender:    Male 
     Female 
 
Race/ Ethnicity:   Caucasian 
     African American 
     Hispanic 
     Others 
 
Height:   __________ m 
 
Weight:   __________ kg 
 
Education Level:   Nil Formal 
<High School 
       High School 
     College 
     Graduate School 
 
Employment:    Paid 
     Retired 
     Unemployed 
     Other 
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Mark the following therapies that you use NOW and have used BEFORE DIAGNOSIS, and 
indicate the number of times per week that you practice these therapies.  
Now Before Diagnosis 
Do you practice any of the following? 
Psychological Therapies:  
Relaxation Techniques 
Times per week: _________________ 
Relaxation Techniques 
Times per week: _________________ 
Imagery 
Times per week: _________________ 
Imagery 
Times per week: _________________ 
Biofeedback 
Times per week: _________________ 
Biofeedback 
Times per week: _________________ 
Hypnosis 
Times per week: _________________ 
Hypnosis 
Times per week: _________________ 
Self- Help Group 
Times per week: _________________ 
Self- Help Group 
Times per week: _________________ 
Healing Therapies:  
Acupuncture 
Times per week: _________________ 
Acupuncture 
Times per week: _________________ 
Aromatherapy 
Times per week: _________________ 
Aromatherapy 
Times per week: _________________ 
Chiropractic Care 
Times per week: _________________ 
Chiropractic Care 
Times per week: _________________ 
Energy Healing (e.g. Reiki) 
Times per week: _________________ 
Energy Healing (e.g. Reiki) 
Times per week: _________________ 
Homeopathy 
Times per week: _________________ 
Homeopathy 
Times per week: _________________ 
Massage Massage 
Times per week: _________________ Times per week: _________________ 
Naturopathy Naturopathy 
Times per week: _________________ Times per week: _________________ 
Yoga Yoga 
Times per week: _________________ Times per week: _________________ 
Lifestyle Diet  Lifestyle Diet  
What type of diet do you follow: What type of diet do you follow: 
“Heart Healthy” “Heart Healthy” 
Vegetarian Vegetarian 
Low Carbohydrate- High Protein Low Carbohydrate- High Protein 
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Macrobiotic Macrobiotic 
“Weight Watchers” 
Other: __________________________ 
“Weight Watchers” 
Other: __________________________ 
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APPENDIX B:  EORTC QUALITY OF LIFE 
QUESTIONNAIRE-C30 AND EORTC QLQ-BR23 
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ENGLISH 
EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the questions yourself by 
circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide 
will 
remain strictly confidential. 
Please fill in your initials: bbbb 
Your birthdate (Day, Month, Year): cececdde 
Today's date (Day, Month, Year): 31 cececdde 
_________________________________________________________________________________________
_ 
Not at A Quite Very 
All Little a Bit Much 
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, dressing, washing 
yourself or using the toilet? 1 2 3 4 
During the past week: Not at A Quite Very 
All Little a Bit Much 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
Please go on to the next page 
ENGLISH 
During the past week: Not at A Quite Very 
All Little a Bit Much 
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment 
interfered with your family life? 1 2 3 4 
27. Has your physical condition or medical treatment 
 34
interfered with your social activities? 1 2 3 4 
28. Has your physical condition or medical treatment 
caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 that 
best applies to you 
29. How would you rate your overall health during the past week? 
1 2 3 4 5 6 7 
Very poor Excellent 
30. How would you rate your overall quality of life during the past week? 
1 2 3 4 5 6 7 
Very poor Excellent 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
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APPENDIX C:  RAND 36-ITEM HEALTH SURVEY 
V2 (SF-36V2) AND UCLA PROSTATE CANCER 
INDEX 
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RAND 36-Item Health Survey v2 (SF-36 v2)  
and  
UCLA PROSTATE CANCER INDEX  
Today’s Date:  
Month Day Year  
The purpose of this questionnaire is to find out about your 
health in general and about how your prostate cancer and any 
treatment you received for it affects your quality of life.  
Please read each question carefully before answering. If you are 
unsure about how to answer a question, please give the best 
answer you can. Remember that there are no right or wrong 
answers. If you have any questions, please call the research staff 
at .  
Your answers to this questionnaire will be kept confidential and 
will be used only for research purposes. The information you 
give will be combined with the responses of other patients 
completing this questionnaire, and you will not be identifiable in 
any way.  
Page 1 These first questions are about your health in general, BOTH 
RELATED and UNRELATED to your prostate cancer. We recognize that 
other diseases you may have in addition to your prostate cancer may affect 
your answers. Please give the best answer you can and remember there are no 
right or wrong answers.  
. In general, would you say your health is: 
1  
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Excellent............................................1 (Circle one number.)  
Very Good.........................................2  
Good..................................................3  
Fair....................................................4  
Poor...................................................5  
. COMPARED TO ONE YEAR AGO, how would you rate your health in 
general now?  
2  
 
Much better now than one year ago....................................1 (Circle one 
number.)  
Somewhat better now than one year ago.............................2  
About the same as one year ago..........................................3  
Somewhat worse now than one year ago............................4  
Much worse now than one year ago....................................5  
3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how 
much?  
 
(Circle 1, 2, or 3 on each line.)  Yes, 
limited 
a lot  
Yes, 
limited 
a little  
No, not 
limited 
at all  
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports.........................  
1  2  3  
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or 
playing golf..................  
1  2  3  
c. Lifting or carrying 
groceries.......................................................  
1  2  3  
d. Climbing several flights of 
stairs...............................................  
1  2  3  
e. Climbing one flight of 
stairs.......................................................  
1  2  3  
f. Bending, kneeling, or 
stooping...................................................  
1  2  3  
g. Walking more than a 1  2  3  
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mile.........................................................  
h. Walking several hundred 
yards...............................................  
1  2  3  
i. Walking one hundred 
yards.....................................................  
1  2  3  
j. Bathing or dressing 
yourself.......................................................  
1  2  3  
Page 2  
4. During the PAST FOUR WEEKS, how much of the time have you had 
any of the following problems with your work or other regular daily 
activities as a result of your physical health?  
 
(Circle one number on each line.)  All 
of 
the 
time 
Most 
of 
the 
time 
Some 
of 
the 
time  
A 
little 
of 
the 
time  
None 
of 
the 
time 
a. Cut down on the amount of time you 
spent on work or other 
activities................... 
1  2  3  4  5  
b. Accomplished less than you would 
like...... 
1  2  3  4  5  
c. Were limited in the kind of work or other 
activities..................................................
...... 
1  2  3  4  5  
d. Had difficulty performing the work or 
other activities (for example, it took 
extra effort)................. 
1  2  3  4  5  
 
5. During the PAST FOUR WEEKS, how much of the time have you had 
any of the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling 
depressed or anxious)?  
 
All 
of 
the 
time 
Most 
of the 
time 
Some 
of the 
time  
A 
little 
of 
the 
None 
of the 
time 
(Circle one number on each line.)  
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time  
a. Cut down on the amount of time you 
spent on work or other 
activities................... 
1  2  3  4  5  
b. Accomplished less than you would 
like...... 
1  2  3  4  5  
c. Did work or other activities less 
carefully than 
usual...................................................
.. 
1  2  3  4  5  
 
6. During the PAST FOUR WEEKS, to what extent has your physical health 
or emotional problems interfered with your normal social activities with 
family, friends, neighbors, or groups?  
 
Not at all.............................................1 (circle one number.)  
Slightly...............................................2  
Moderately.........................................3  
Quite a bit...........................................4  
Extremely...........................................5 
Page 3  
. How much BODILY pain have you had during the PAST FOUR WEEKS? 
7 
 
None...................................................1 (circle one number.)  
Very mild...........................................2  
Mild....................................................3  
Moderate............................................4  
Severe.................................................5  
Very severe........................................6  
8. During the PAST FOUR WEEKS, how much did pain interfere with your 
normal work (including both work outside the home and housework)?  
 
Not at all.............................................1 (Circle one number.)  
A little bit...........................................2  
Moderately.........................................3  
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Quite a bit...........................................4  
Extremely...........................................5  
9. These questions are about how you feel and how things have been with 
you during the PAST FOUR WEEKS. For each question, please give 
the one answer that comes closest to the way you have been feeling. How 
much of the time during the PAST FOUR WEEKS...  
 
(Circle one number on each line.)  All of 
the 
time 
Most 
of the 
time  
Some 
of the 
time  
A 
little 
of the 
time  
None 
of the 
time  
a. Did you feel full of 
life?...........................  
1  2  3  4  5  
b. Have you been very 
nervous?...................  
1  2  3  4  5  
c. Have you felt so down in the 
dumps that nothing could cheer 
you up?..............  
1  2  3  4  5  
d. Have you felt calm and 
peaceful?.............  
1  2  3  4  5  
e. Did you have a lot of 
energy?...................  
1  2  3  4  5  
1  2  3  4  5  f. Have you felt downhearted and 
depressed?  
4  1  2  3  g. Did you feel worn 
out?.............................  
5  
h. Have you been 
happy?..............................  
1  2  3  4  5  
i. Did you feel 
tired?....................................  
1  2  3  4  5  
Page 4  
10. During the PAST FOUR WEEKS, how much of the time has your 
physical health or emotional problems interfered with your social 
activities (like visiting with friends, relatives, etc.)?  
 
All of the time....................................1 (Circle one number.)  
Most of the time.................................2  
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Some of the time................................3  
A little of the time..............................4  
None of the time.................................5  
1. How TRUE or FALSE is each of the following statements for you?  
1 
 
(Circle one number on each 
line.)  
Definitely 
true  
Mostly 
true  
Don’t 
know 
Mostly 
false  
Definitely 
false  
1  2  3  4  5  a. I seem to get sick a little 
easier than other 
people.........................  
1  2  3  4  b. I am as healthy as 
anyone I know  
5  
c. I expect my health to get 
worse..  
1  2  3  4  5  
1  2  3  4  5  d. My health is 
excellent.................  
 
Please continue on next page. 
Page 5  
URINARY FUNCTION  
This section is about your urinary habits. Please consider ONLY THE LAST 
4 WEEKS.  
 
2. Over the LAST 4 WEEKS, how often have you leaked urine?  
1  
 
Every day......................................1 (Circle one number.)  
About once a week........................2  
Less than once a week...................3  
Not at all........................................4  
 
13. Which of the following best describes your urinary control during the 
LAST 4 WEEKS?  
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No control whatsoever..................1 (Circle one number.)  
Frequent dribbling.........................2  
Occasional dribbling.....................3  
Total control..................................4  
 
14. How many pads or adult diapers per day did you usually use to control 
leakage during the LAST 4 WEEKS?  
 
3 or more pads per day..................1 (Circle one number.)  
1-2 pads per day............................2  
No pads.........................................3  
 
5. How big a problem, if any, has each of the following been for you?  
1  
 
(Circle one number on each 
line.)  
No 
problem 
Very 
small 
problem 
Small 
problem 
Moderate 
problem  
Big 
problem 
a. Dripping urine or wetting 
your 
pants?............................
...... 
0  1  2  3  4  
b. Urine leakage interfering 
with your sexual 
activity?................... 
0  1  2  3  4  
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16. Overall, how big a problem has your urinary function been for you 
during the LAST 4 WEEKS?  
 
No problem...................................1 (Circle one number.)  
Very small problem.......................2  
Small problem...............................3  
Moderate problem.........................4  
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Big problem..................................5  
 
BOWEL HABITS  
This section is about your bowel habits and abdominal pain. Please consider 
ONLY THE LAST 4 WEEKS.  
 
17. How often have you had rectal urgency (felt like you had to pass stool, 
but did not) during the LAST 4 WEEKS?  
 
More than once a day....................1 (Circle one number.)  
About once a day..........................2  
More than once a week.................3  
About once a week........................4  
Rarely or never..............................5  
 
18. How often have you had stools (bowel movements) that were loose or 
liquid (no form, watery, mushy) during the LAST 4 WEEKS?  
 
Never.............................................1 (Circle one number.)  
Rarely............................................2  
About half the time.......................3  
Usually..........................................4  
Always..........................................5  
 
19. How much distress have your bowel movements caused you during the 
LAST 4 WEEKS?  
 
Severe distress...............................1 (Circle one number.)  
Moderate distress..........................2  
A little distress..............................3  
 44
No distress.....................................4  
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20. How often have you had crampy pain in your abdomen or pelvis during 
the LAST 4 WEEKS?  
 
Several times a day.......................1 (Circle one number.)  
About once a day..........................2  
Several times a week.....................3  
About once a week........................4  
About once this month..................5  
Rarely or never..............................6  
 
21. Overall, how big a problem have your bowel habits been for you during 
the LAST 4 WEEKS?  
 
Big problem..................................1 (Circle one number.)  
Moderate problem.........................2  
Small problem...............................3  
Very small problem.......................4  
No problem...................................5  
 
SEXUAL FUNCTION  
The next section is about your sexual function and sexual satisfaction. Many 
of the questions are very personal, but they will help us understand the 
important issues that you face every day. Remember that your answers to 
this questionnaire will be kept confidential and will be used only for research 
purposes. Please answer honestly about THE LAST 4 WEEKS ONLY.  
 
2. How would you rate each of the following during the LAST 4 WEEKS? 
2  
 
(Circle one number on each line.)  Very 
Poor  
Poor Fair Good  Very 
Good  
a. Your level of sexual 1  2  3  4  5  
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desire?.......................  
b. Your ability to have an 
erection?...............  
1  2  3  4  5  
c. Your ability to reach orgasm 
(climax)?.....  
1  2  3  4  5  
 
3. How would you describe the usual QUALITY of your erections?  
2  
 
None at 
all..................................................................................1  
(Circle one 
number.) 
Not firm enough for any sexual activity....................................2  
Firm enough for masturbation and foreplay only......................3  
Firm enough for intercourse.......................................................4  
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4. How would you describe the FREQUENCY of your erections?  
2  
 
I NEVER had an erection when I wanted 
one.....................................1  
(Circle one 
number.)  
I had an erection LESS THAN HALF the time I wanted one.............2  
I had an erection ABOUT HALF the time I wanted one.....................3  
I had an erection MORE THAN HALF the time I wanted one...........4  
I had an erection WHENEVER I wanted one......................................5  
 
5. How often have you awakened in the morning or night with an erection?  
2  
 
Never..........................................................................................1  (Circle 
one 
number.) 
Seldom (less than 25% of the time)...........................................2  
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Not often (less than half the time)..............................................3  
Often (more than half the time)..................................................4  
Very often (more than 75% of the time)....................................5  
 
6. During the LAST 4 WEEKS did you have vaginal or anal intercourse?  
2  
 
No...................................................1 (Circle one number.)  
Yes, once........................................2  
Yes, more than once.......................3  
 
27. Overall, how would you rate your ability to function sexually during the LAST 
4 WEEKS?  
 
Very poor........................................1 (Circle one number.)  
Poor................................................2  
Fair..................................................3  
Good...............................................4  
Very good.......................................5  
 
28. Overall, how big a problem has your sexual function been for you during the 
LAST 4 WEEKS?  
 
No problem.....................................1 (Circle one number.)  
Very small problem........................2  
Small problem................................3  
Moderate problem..........................4  
Big problem....................................5  
Page 9  
DEMOGRAPHIC & BRIEF MEDICAL QUESTIONS 
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 29. How old were you on your last birthday?  
 
_______ (Enter age.)  
30. How do you describe yourself?  
White/Caucasian..............................................1 (Circle one number.)  
Black/African-American.................................2  
Latino/Hispanic...............................................3  
Asian/Pacific Islander......................................4  
Multi-Racial.....................................................5  
Other:  
31. Which of the following best describes your current relationship?  
Living with spouse or partner........................................1 (Circle one 
number.)  
In a significant relationship, but not living together......2  
Not in a significant relationship.....................................3  
32. How much school did you complete?  
Grade school or less..........................................1 (Circle one 
number.)  
Some high school or technical school...............2  
High school or technical school graduate.........3  
Some college.....................................................4  
College Graduate...............................................5  
Graduate or professional school after college...6  
Please continue on next page. 
 48
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3. Have you ever had any of the following medical conditions? 
3  
 
(Please circle yes or no for every item.)  Yes No  
a. Diabetes …..……………………………………. 1  0  
b. Heart attack, chest pain ……………………….... 1  0  
c. Stroke …………………………………………... 1  0  
d. Amputation …………………………………….. 1  0  
e. Circulation problems in your legs or feet .......…. 1  0  
f. Asthma, emphysema, breathing problems ..........  1  0  
g. Stomach ulcer, irritable bowel …………………. 1  0  
h. Kidney disease ………………………………..... 1  0  
I. Major depression ……………………………….  1  0  
j. Seizures ………………………………………… 1  0  
k. Alcoholism or alcohol problems……………....... 1  0  
l. Drug problems………………………………..…  1  0  
m. Current or past cigarette smoker…...………….  1  0  
 
34. Are you now working at a paying job?  
Yes, full-time....................................................1 (Circle one number.)  
Yes, part time....................................................2  
No, but looking for a job..................................3  
No, retired.........................................................4  
No, disabled......................................................5  
Comments:  
Thank you very much for your time! Please remember to mail 
your completed questionnaire in the supplied envelope.  
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INSTRUCTIONS FOR SUBMITTING PROTOCOLS FOR REVIEW BY 
THE BIOMEDICAL SCIENCES INSTITUTIONAL REVIEW BOARD 
THE OHIO STATE UNIVERSITY 
 
 
 
Protocols received in the Office of Research Risks after the deadline date (first 
Monday of each month) will be scheduled for the following month's meeting.  
(Exception:  The Monday deadline is moved to the Friday before Monday Holidays.)  
If all time slots are filled and a protocol is received on or before the deadline date, 
the protocol will be scheduled for the following month's meeting.  Only protocols 
that are complete as defined below will be scheduled for review.  Incomplete 
protocols will be returned to the principal investigator. 
 
SUBMIT FIVE (5) SETS OF THE COMPLETE PROTOCOL (Original + 4 copies) 
including: 
• Summary Sheets  
• Cover Page with original signatures 
• Advertisement (if applicable) 
• Consent form 
• Research proposal 
 IRB Administrative Assistant, Biomedical Sciences Human Subjects IRB 
 Office of Research Risks Protection 
 Room 300, Research Foundation Building 
 1960 Kenny Road 
 Campus 
 (Phone 292-9046) 
 
 
1. SUMMARY SHEETS with Cover Page: 
 
 a. Cover page (Form HS-029) must have original signatures of all principal and co-
investigators and respective department chairs. 
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 b. The abstract (overview of research) should be sufficiently informative to allow the 
reviewers a broad understanding of the research. 
 
 c. Do not use abbreviations for medical terminology. 
 
 d. Initial use of drug name should identify generic name in parentheses. 
 
 e. Complete each section - do not leave any question unanswered.  Explain all reasonably 
expected risks. 
 
2. ADVERTISEMENT should be limited to: 
 
 a. The name and address of the clinical investigator; 
 
 b. The purpose of the research and, in summary form, the eligibility criteria that will be 
used to admit subjects into the study; 
 
 c. A straightforward and truthful description of the benefit (e.g., payments or free 
treatment) to the subject from participation in the study; and 
 
 d. The location of the research and the person to contact for further information. 
 
 Note:  No claims should be made, either explicitly or implicitly, that the drug or device is safe 
or effective for the purposes under investigation, or that the drug or device is in any way 
equivalent or superior to any other drug or device. 
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3. CONSENT FORM HS-028A (Rev. 7/93) 
 
 a. It is emphasized that the basic components and the language of the consent form cannot be 
altered.  The consent form should be a single, continuous document of as many pages as 
necessary.  The information should be written in language understandable to the subject.  
Explain medical terminology in LAYMEN'S LANGUAGE. 
 
 b. Any payment and/or additional expenses to subject must be addressed in the consent form. 
 
 c. If blood samples are to be drawn, state how many samples and the total volume in ounces.  List 
standard risks:  bruise at blood drawing site, discomfort or pain at the site, infection, fainting.  If 
arterial stick, must also include artery damage with possible loss of circulation and gangrene. 
 
 d. Include copies of all other standard procedure consent forms that pertain to the protocol; i.e., 
anesthesia, cardiac catheter, endoscopy, etc. 
 
 e. For NO RISK protocols, waiver of written consent may be requested.  Examples of activities 
that might be considered for waiver of written consent are surveys or questionnaires or other 
protocols involving no bodily invasion.  (Venipuncture is considered minimal risk and must be 
accompanied by a consent form.) 
 
4. RESEARCH PROPOSAL - (separate from the Summary Sheets; e.g., proposal that will be 
forwarded to an external funding agency, or as it will be presented for internal review process at the 
department or college level if the research activity is not to be supported by an external funding 
agency): 
 
 a. Introductory background information that reviews information relevant to this research.  This 
review should be sufficiently broad to serve as the justification for the conduct of this research.  
In the case of drug studies, complete information on the drug should be provided to the IRB.  
Also, in situations when this research is being done on humans for the first time, the results of all 
relevant studies on animals must be presented in the research proposal. 
 
 b. Clearly stated objectives of the research. 
 
 c. Design of the study. 
 
 d. Methods employed in the collection and analysis of the data.  Particular attention should be paid 
to justifying subjecting human beings to the risks of the research. 
 
 e. Discussion of the significance of the research and impact on science or human welfare. 
 
 f. Bibliography adequate to support the proposal statements. 
 
 g. If the proposal has been submitted to other review committees (i.e., Medical Radionuclide 
Committee, Maternal-Fetal Committee, James Cancer Center Clinical Scientific Review 
Committee, etc.) attach all correspondence and relevant material from the respective 
committees.  The investigator is responsible for obtaining approval from the various committees. 
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HS-029 (Rev. 7/93) 
CATEGORIES OF RESEARCH ELIGIBLE FOR EXPEDITED 
REVIEW BY HUMAN SUBJECTS REVIEW COMMITTEE 
 
 
Research activities involving no more than minimal risk and in which the only involvement of human subjects will 
be in one or more of the following categories (carried out through standard methods) may be reviewed through the 
expedited review procedure: 
 
 Collection of:  hair and nail clippings, in a nondisfiguring manner; deciduous teeth; and permanent teeth if patient care indicates a need for extraction. 
 
 Collection of excreta and external secretions including sweat, uncannulated saliva, placenta removed at delivery, and amniotic fluid at the time of rupture of the membrane prior to or during 
labor. 
 
 Recording of data from subjects 18 years of age or older using non-invasive procedures routinely employed in clinical practice.  This includes the use of physical sensors that are applied either to 
the surface of the body or at a distance and do not involve input of matter or significant amounts of 
energy into the subject or an invasion of the subject's privacy.  It also includes such procedures as 
weighing, testing sensory acuity, electrocardiography, electroencephalography, thermography, 
detection of naturally occurring radioactivity, diagnostic echography, and electroretinography.  It 
does not include exposure to electromagnetic radiation outside the visible range; i.e., x-rays, 
microwaves. 
 
 Collection of blood samples by venipuncture, in amounts not exceeding 450 milliliters in an eight-week period and no more often than two times per week, from subjects 18 years of age or older 
and who are in good health and not pregnant. 
 
 Collection of both supra- and subgingival dental plaque and calculus, provided the procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in 
accordance with accepted prophylactic techniques. 
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 Voice recordings made for research purposes such as investigations of speech defects. 
 
 
 Moderate exercise by healthy volunteers. 
 
 The study of existing data, documents, records, pathological specimens, or diagnostic specimens. 
 
 
 
 Research on individual or group behavior or characteristics of individuals, such as studies of perception, cognition, game theory, or test development, where the investigator does not 
manipulate subjects' behavior and the research will not involve stress to subjects. 
 
 
 Research on drugs or devices for which an investigational new drug exemption or an investigational device exemption is not required. 
 
 
(For an EXPEDITED REVIEW check the appropriate box and return with the complete protocol.) 
 
 
 
HS-029D (11/92) 
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Office Use:  
Protocol No.  THE OHIO STATE UNIVERSITY 
BIOMEDICAL SCIENCES 
INSTITUTIONAL REVIEW BOARD 
Date 
Received:  
 
Protocols received in the Office of Research Risks Protection after the deadline date (first Monday of each month) will be scheduled for 
the following month's meeting.  Exception:  The deadline is moved to the Friday before Monday holidays  If all time slots are filled and a 
protocol is received on or before the deadline date, the protocol will be scheduled for the following month's meeting.  The IRB meets on 
the third Monday of each month).  Only protocols that are complete will be scheduled for review.  Incomplete protocols will be returned. 
 
Principal Investigator: Steven K. Clinton, MD, Ph.D.   
OSU Faculty or 
approved PI status 
Typed Name 
 
Signature 
Academic 
Title: 
Associate Professor of Internal 
Medicine 
614.293.8396 614.293.7525 
  
Phone 
No.
 
Fax No. 
 
Colleg
e: 
Medicine and Public Health Department/No. Internal Medicine/ 25256 
  
A 434 Starling Loving Hall, 320 W. 10th Avenue Campus 
Address: 
 
Co-
Investigators: 
Elizabeth C. Miller, MS, RD   
 Typed Name  Signature 
 Eileen C. Ang   
  Typed Name Signature 
 
Protocol 
Title: 
XXX 
 
 
 
Department Chair(s) 
Endorsement: 
Michael Caliguiri, MD   
  
Signature Typed Name 
 Michael Grever, MD   
 
Typed Name 
 
Signature 
 
Proposed Research Involves: 
YES NO  
Investigational Drug(s) or investigational use of marketed drugs(s).  If yes, provide:   
IND 
Number  
 Issued 
to 
 Generic 
Name: 
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  Investigational Devices(s).  If yes, indicate NSR                ; or SR                ; if SR, provide:  IDE 
Number                     ; Issued to:                                     . 
 
  Radioactive Drugs or Unusual Exposure to External Radiation.  Approval by the Medical 
Radionuclide Committee (Phone:  292-0122) is required prior to activation.  Investigator is 
responsible for obtaining approval from both committees. 
 
  Cancer-related Activities.  Approval by the James Cancer Center Clinical Scientific Review 
Committee (Phone:  293-4976) is required prior to activation.  Investigator is responsible for 
obtaining approval from both committees. 
 
  Pregnant Women.  Approval by Maternal-Fetal committee (Phone:  293-8736) is required prior to 
activation.  Investigator is responsible for obtaining approval from both committees. 
 
  Minors (Under 18 years of age) 
 
  Cognitively Impaired 
 
  Fetuses/In Vitro Fertilization 
 
  Prisoners 
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BIOMEDICAL SCIENCES 
SUMMARY SHEETS 
 
ADDRESS EACH ITEM IN A COMPLETE AND CONCISE MANNER.  (Do not leave any item blank 
with "See attached.)  Use continuation pages when necessary. 
 
1. Abstract (overview of research) 
 
Background: The use of complementary and alternative medicine (CAM) has become significantly more 
prevalent over the past decade, and it may be more common among cancer patients. CAM are used for a 
variety of reasons such as; minimizing the effect of conventional treatment, enhancing quality of life or the 
desire to take control of health (Kao, 2000). The effects of CAM use during cancer treatment are largely 
unstudied, and it is possible that certain types of CAM, such as nutritional supplements and altermative 
medications, may impact the efficacy of radiation treatment. There are very few studies investigating the 
prevalence of CAM use among persons undergoing radiation treatment.  This information is critical for 
future trials to investigate the effects of CAM therapies on cancer treatment, clinical outcomes, and quality 
of life.  
 
Objective: Our objective is to quantify the use of CAM therapies in men with prostate cancer and women 
with breast cancer who are currently undergoing radiation therapy at The James Cancer Hospital and Solove 
Research Institute.  We will collect information on the use of many different CAM therapies with an emphasis 
on nutritional supplement and alternative medication use.  We will also determine if patients change their 
patterns of supplement and alternative medication use during or after radiation treatment and we will use a 
reliable and valid questionnaire to measure quality of life.   
 
 Design: This study will consist of a brief interview and a take-home questionnaire at three different time 
points for a total of 50 men with prostate cancer and 50 women with breast cancer who are scheduled to begin 
radiation therapy at The James Cancer Hospital and Solove Research Institute. We will ask all eligible patients 
to answer a few questions and to bring their supplement bottles to the clinic where we will photocopy the 
labels for our records.  Descriptive statistics will be completed to provide information on the frequency of 
different types of CAM therapies and associations between specific CAM therapies and demographic 
characteristics and quality of life. 
 
2. Describe the requirements for a subject population and explain the rationale for using in this population 
special groups such as prisoners, children, the mentally disabled or groups whose ability to give voluntary 
informed consent may be in question.  Address means of pregnancy screening for females. 
 
 None of the special groups above will be enrolled in this study. 
 Pregnant women will not be enrolled in this study. 
 
 The requirements include the following; study participants must: 
 
• Be currently scheduled to undergo external beam radiation therapy or brachytherapy at The James Cancer Hospital and 
Solove Research Institute for primary treatment for newly diagnosed prostate or breast cancer.  
• Not have known metastatic disease. 
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3. Describe and assess any potential risks - physical, psychological, social, legal, financial, or other - and 
assess the likelihood and seriousness of such risks.  If methods of research create potential risks, describe 
other methods, if any, that were considered and why they will not be used. 
 
There are no significant risks involved with participating in this study.  Eligible patients who do not wish to 
disclose their use of nutritional supplements will not be included in the study.  
 
4. Describe consent procedures to be followed, including how and where informed consent will be 
obtained.  (The use of a finder's fee for recruiting subjects is not permitted.) 
 
All patients will undergo an informed consent process. The study coordinator will call eligible patients prior to 
the initiation of radiation therapy and will describe the purpose of the survey. Patients will be informed that 
there is no risk to them and no additional visits to the clinic are required for the purposes of this study. Patients 
who do not wish to participate will not be included in the study. Patients will be asked to sign the informed 
consent form during their simulation visit, before the initiation of radiation therapy. 
 
 
HS-029B (Rev. 7/93) 
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BIOMEDICAL SCIENCES 
SUMMARY SHEETS 
 
ADDRESS EACH ITEM IN A COMPLETE AND CONCISE MANNER.  (Do not leave any item blank 
with "See attached.)  Use continuation pages when necessary. 
 
5. Describe procedures (including confidentiality safeguards) for protecting against or minimizing potential 
risks and an assessment of their likely effectiveness. 
 
We will review each patients medical chart to obtain demographic information.  This information in addition 
to the study documents will be kept in a locked filing cabinet in Starling Loving Hall and only persons directly 
involved in the study (Steven K. Clinton, Elizabeth Miller and Eileen Ang) will have access to the study files. 
 
The study poses no obvious risk to the patient. 
 
Patient names will not be used in any publication resulting from this study. 
 
 
6. Assess the potential benefits to be gained by the individual subject, as well as benefits which may accrue 
to society in general as a result of the planned work. 
 
The individual subject may not benefit from this study. There is no obvious risk of this study because it is 
simply a collection of information at three different time points, consisting of a brief interview and a take-
home questionnaire.  
 
The benefits to the society may be large. This study will describe nutritional supplement and alternative 
medicine use in men with prostate cancer and women with breast cancer who are undergoing radiation therapy 
and to determine the association between supplement usage patterns with demographic characteristics and 
reported quality of life. This information will be useful for future trials to investigate the effects of CAM 
therapies on cancer treatment, clinical outcomes and quality of life. 
 
7. Compare the risks versus the benefits. 
 
 The risk to the patient is minimal while the potential benefits to our society are large.  
 
 
8. Will the subjects for the study be paid for participating in this study?  Yes   No X    
If yes, how much?  
  
 Will subjects be paid for selected activities (e.g., blood drawing) or for general 
participation in the study? 
* NOTE:  All information concerning payments, including the amount and schedule of payment, must be included in the consent form. 
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 Is there any other inducement?  Yes   No X   If so, please describe. 
 
 
9. Will advertising be used to recruit subjects?  Yes   No X   If yes, attach a copy of the proposed 
advertisement. 
  
 
        
  SOURCE OF FUNDING FOR PROPOSED RESEARCH:  (Check A or B)   
        
  A. OSURF:  Sponsor  RF Proposal/Project 
No. 
   
        
        
  B. Other (Identify)    
        
  Information about the funding/sponsorship of human subjects research activities is 
required for administrative purposes.  Such information is generally not required as part of 
the human subjects review process. 
  
        
HS-029C (Rev. 7/93) 
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THE OHIO STATE UNIVERSITY Protocol No. ________________ 
 
CONSENT TO INVESTIGATIONAL TREATMENT OR PROCEDURE 
 
I, _________________________, hereby authorize or direct Steven K. Clinton, MD, Ph.D., associates or 
assistants of his/her choosing, to perform the following treatment or procedure (describe in general terms), 
 
To ask me questions about my use of nutritional supplements (vitamins, minerals, herbs, botanicals, etc.) and for 
me to fill in a questionnaire on quality of life and alternative therapies I use.  
 
To allow the investigators to photocopy ingredient content of supplement consumed.  
 
Examples of questions that I may be asked include questions about the dose, formulation, brand name, and the 
number of years I have taken a specific nutritional supplement, the types and frequency of alternative therapies I 
use and general quality of life questions. These questions should take no more than ten (10) minutes to answer. 
 
 upon ____________________________________. 
(myself or name of subject)             
 
The experimental (research) portion of the treatment or procedure is: 
 
Approximately 50 men and 50 women will be enrolled in this study.  
 
If I decide to participate in this study, I will answer a brief questionnaire about my use of Complementary and 
Alternative Medicine practices and a quality of life questionnaire.  In addition I will bring in the bottles of all of 
the nutritional supplements and alternative medications I currently use to be photocopied by the study coordinator.  
 
This process will be repeated three times over the course of approximately two to three months:  at the beginning 
of radiation treatment, at the end of radiation treatment, and at my first follow up appointment.   
 
Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to which I am otherwise 
entitled. 
 
I will not be paid for my participation in this study, nor will this study result in any extra cost to me. 
 
This is done as part of an investigation entitled: 
XXX 
 
1. Purpose of the procedure or treatment: 
 
To evaluate the use of complementary and alternative medicine practices among men with prostate cancer and women with breast cancer who are currently undergoing 
radiation therapy at The James Cancer Hospital and Solove Research Institute.  
 
To determine if the use of complementary and alternative medicine is related to quality of life in breast 
cancer and prostate cancer patients undergoing radiation therapy.  
 
2. Possible appropriate alternative procedure or treatment (not to participate in the study is always an 
option): 
  
 I may choose not to participate without affecting my current or future medical care.  
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3. Discomforts and risks reasonably to be expected: 
 
 There are no risks associated with participation in this study. 
 
4. Possible benefits for subjects/society: 
 
I may not benefit in any way from this study, nor is there any risk to me.  
 
The possible benefits to society include a better understanding of complementary and alternative medicine use in men with prostate cancer or women with breast cancer 
who are undergoing radiation therapy.  
 
5. Anticipated duration of subject's participation (including number of visits): 
 
 This study consists of a brief interview during my regularly scheduled appointment and a take home questionnaire. 
 
 No additional visits to the clinic are required for this study.  
 
 
I hereby acknowledge that ____________________ has provided information about the procedure described above, about my 
rights as a subject, and he/she answered all questions to my satisfaction.  I understand that I may contact him/her at Phone 
No. 614.293.8396 should I have additional questions.  He/She has explained the risks described above and I understand them; 
he/she has also offered to explain all possible risks or complications. 
 
I understand that, where appropriate, the U.S. Food and Drug Administration may inspect records 
pertaining to this study.  I understand further that records obtained during my participation in this study 
that may contain my name or other personal identifiers may be made available to the sponsor of this study.  
Beyond this, I understand that my participation will remain confidential. 
 
I understand that I am free to withdraw my consent and participation in this project at any time after 
notifying the project director without prejudicing future care.  No guarantee has been given to me 
concerning this treatment or procedure. 
 
I understand in signing this form that, beyond giving consent, I am not waiving any legal rights that I might 
otherwise have, and I am not releasing the investigator, the sponsor, the institution, or its agents from any 
legal liability for damages that they might otherwise have. 
 
In the event of injury resulting from participation in this study, I also understand that immediate medical 
treatment is available at University Hospitals of The Ohio State University and that the costs of such 
treatment will be at my expense; financial compensation beyond that required by law is not available.  
Questions about this should be directed to the Office of Research Risks at 292-5958. 
 
I have read and fully understand the consent form.  I sign it freely and voluntarily.  A copy has been given 
to me. 
 
 
 
 
    
AM 
P
M 
Signe
d
Dat
e: 
Tim
e 
 (Subject) 
 16
 
Witness 
(es) 
   
if 
required 
  (Person Authorized to Consent for Subject if Required) 
    
 
 
 
 
 
 
I certify that I have personally completed all blanks in this form and explained them to the subject or 
his/her representative before requesting the subject or his/her representative to sign it. 
 
 
 
 
  Dat
e: 
Signe
d 
 (Signature of Project Director or his/her Authorized Representative) 
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THE OHIO STATE UNIVERSITY 
BIOMEDICAL SCIENCES 
HUMAN SUBJECTS REVIEW COMMITTEE 
 
 
C H E C K L I S T * FOR PRINCIPAL INVESTIGATOR'S USE - DO NOT RETURN 
 
___1. Are there five (5) copies of the complete protocol?  (A complete protocol consists of four major 
components - Biomedical Summary Sheets, Advertisement, Consent Form and Research Proposal.) 
 
BIOMEDICAL SUMMARY SHEETS 
 
___ 2. Have all (original) signatures of the investigators and department chairs been obtained?  (When more 
than one department is involved, the signature of each chair must be obtained.) 
 
___ 3. Are the summary sheets written in sufficient detail and lay terminology to all the committee to make an 
informed decision? 
 
___ 4. Are all items filled-in?  (Continuation pages are allowed when there is insufficient space for entire 
response.  Do not leave blank or indicate "See Attached".) 
 
___ 5. If the summary sheets have been re-typed, has the wording of Items 1 through 9 been re-typed to 
correspond with the response? 
 
___ 6. Has the Investigational Drug Number (IND) or Investigational Device Number (IDE) been included? 
 
CONSENT FORM (Rev. 11/92) 
 
___ 7. Is the standard wording of the consent form in bold type or highlighted in such a way that it stands out 
from the fill-in portions? 
 
___ 8. Is the consent form written in language easily understood by a lay person; and, with enough detail to 
inform subjects exactly what will be expected of them? 
 
___ 9. If the study is a double blind and/or randomized study, is it explained in lay language? 
 
___10.  Are all abbreviations spelled out? 
 
___11. If females are to participate in the study, has it been clarified as to whether they may be pregnant, or 
what means will be used to document such? 
 
___12. If blood is to be drawn, has the amount been stated in ounces and the number of samples indicated? 
 
___13. Have the risks of blood drawing been specified?  (Bruise at blood drawing site, discomfort or pain at the 
site, infection, fainting.) 
 
___14. If subjects will incur any expenses as a result of participating in the study, have these expenses been 
specified with regard to who will be responsible for payment; i.e., subject, insurance, Medicare, etc? 
 
___15. Are subjects being paid for participation?  If so, has it been shown? 
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RESEARCH PROPOSAL 
 
___ 1. In the case of drug studies, has complete information on the drug been included? 
 
___ 2. Has a bibliography been included? 
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THE OHIO STATE UNIVERSITY Protocol No. 2002C0263 
                    February, 2008 version 
CONSENT TO INVESTIGATIONAL TREATMENT OR PROCEDURE 
 
I, _________________________, hereby authorize or direct Steven K. Clinton, MD, Ph.D., associates or assistants of his/her 
choosing, to perform the following treatment or procedure (describe in general terms), 
 
To ask me questions about my use of nutritional supplements (vitamins, minerals, herbs, botanicals, etc.) and for me to fill in a 
questionnaire on quality of life and alternative therapies I use.  
 
To allow the investigators to photocopy ingredient content of supplement consumed.  
 
Examples of questions that I may be asked include questions about the dose, formulation, brand name, and the number of years I have 
taken a specific nutritional supplement, the types and frequency of alternative therapies I use and general quality of life questions. These 
questions should take no more than ten (10) minutes to answer. 
 
 upon ____________________________________. 
(myself or name of subject)                
 
The experimental (research) portion of the treatment or procedure is: 
 
Approximately 60 men and 60 women will be enrolled in this study.  
 
If I decide to participate in this study, I will answer a brief questionnaire about my use of Complementary and Alternative Medicine 
practices and a quality of life questionnaire.  In addition I will bring in the bottles of all of the nutritional supplements and alternative 
medications I currently use to be photocopied by the study coordinator.  
 
This process will be repeated three times over the course of approximately two to three months:  
For radiation therapy patients: at the beginning of radiation treatment, at the end of radiation treatment, and at my first follow up 
appointment.   
For brachytherapy patients: before brachytherapy, 5 weeks after brachytherapy and 11 weeks after brachytherapy during their clinical 
visits with Dr. Clinton. 
 
Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to which I am otherwise entitled. 
 
I will not be paid for my participation in this study, nor will this study result in any extra cost to me. 
 
This is done as part of an investigation entitled: 
 
Use of nutritional supplements and CAM (complementary and alternative medicine) by prostate and breast cancer patients undergoing 
radiotherapy 
 
1. Purpose of the procedure or treatment: 
 
To evaluate the use of complementary and alternative medicine practices among men with prostate cancer and women with breast 
cancer who are currently undergoing radiation therapy at The James Cancer Hospital and Solove Research Institute.  
 
To determine if the use of complementary and alternative medicine is related to quality of life in breast cancer and prostate cancer 
patients undergoing radiation therapy.  
 
2. Possible appropriate alternative procedure or treatment (not to participate in the study is always an option): 
  
 I may choose not to participate without affecting my current or future medical care.  
 
3. Discomforts and risks reasonably to be expected: 
 
 21
 There are no risks associated with participation in this study. 
 
 
4. Possible benefits for subjects/society: 
 
I may not benefit in any way from this study, nor is there any risk to me.  
 
The possible benefits to society include a better understanding of complementary and alternative medicine use in men with prostate 
cancer or women with breast cancer who are undergoing radiation therapy.  
 
5. Anticipated duration of subject's participation (including number of visits): 
 
 This study consists of a brief interview during my regularly scheduled appointment and a take home questionnaire. 
 
 No additional visits to the clinic are required for this study.  
 
I hereby acknowledge that ____________________ has provided information about the procedure described above, about my 
rights as a subject, and he/she answered all questions to my satisfaction.  I understand that I may contact him/her at Phone 
No. 614.293.8396 should I have additional questions.  He/She has explained the risks described above and I understand them; 
he/she has also offered to explain all possible risks or complications. 
 
I understand that, where appropriate, the U.S. Food and Drug Administration may inspect records pertaining to this study.  I 
understand further that records obtained during my participation in this study that may contain my name or other personal 
identifiers may be made available to the sponsor of this study.  Beyond this, I understand that my participation will remain 
confidential. 
 
I understand that I am free to withdraw my consent and participation in this project at any time after notifying the project 
director without prejudicing future care.  No guarantee has been given to me concerning this treatment or procedure. 
 
I understand in signing this form that, beyond giving consent, I am not waiving any legal rights that I might otherwise have, and I 
am not releasing the investigator, the sponsor, the institution, or its agents from any legal liability for damages that they might 
otherwise have. 
 
In the event of injury resulting from participation in this study, I also understand that immediate medical treatment is available 
at University Hospitals of The Ohio State University and that the costs of such treatment will be at my expense; financial 
compensation beyond that required by law is not available.  Questions about this should be directed to the Office of Research 
Risks at 292-5958. 
 
I have read and fully understand the consent form.  I sign it freely and voluntarily.  A copy has been given to me. 
 
 
 
   
AM 
PM Date: Time Signed 
 
 (Subject) 
 
 Witness (es)   
(Person Authorized to Consent for Subject if Required) if required   
    
 
 
 
 
 
I certify that I have personally completed all blanks in this form and explained them to the subject or his/her representative 
before requesting the subject or his/her representative to sign it. 
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 Date: Signed 
(Signature of Project Director or his/her Authorized 
Representative) 
 
 
 
HS-028A  (Rev. 7/93 
) 
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APPENDIX F:  HIPAA FORMS 
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THE OHIO STATE UNIVERSITY 
HIPAA RESEARCH AUTHORIZATION FORM 
 
Beginning April 14, 2003, the new HIPAA Privacy Rule requires that Ohio State University Principal 
Investigators (PIs) provide research subjects with greater detail than what is currently included in the 
IRB-approved consent form concerning how a subject’s past, present and future health-related 
information (collectively, Protected Health Information or PHI) will be used, shared and protected during 
the research. Specifically, the Privacy Rule now requires that PIs inform subjects of the following:  1) 
what specific kinds of information will be used or disclosed to others during the course of the research; 2) 
the specific identities of collaborating investigators, sponsor companies or sponsor agencies that will 
potentially receive copies of subjects’ PHI during the research; 3) that subjects have a right to review their 
research-related PHI; and 4) that subjects have the express right to revoke their authorizations for the 
release of PHI at any time. 
 
To meet these new requirements, PIs using PHI obtained from medical or research records from the Ohio 
State University Hospitals, The Arthur G. James Cancer Hospital and Richard J. Solove Research 
Institute, OSU & Harding Behavioral Health Care & Medicine, the Ohio State University Hospitals East 
and the Primary Care Network (the University Health System), or other University operated health 
centers or clinics, must now complete and receive a signed copy of the University’s “Authorization to Use 
Personal Health Information in Research” form  (the Authorization) below from subjects enrolling in 
research studies on or after April 14th (or be granted a waiver by a HIPAA Privacy Board) in addition to 
obtaining a signed IRB-approved consent form.  The form will need to be carefully prepared by PIs to 
ensure that the Authorization covers ALL of the necessary uses and disclosures of personal health 
information used in clinical research.  Failure to do so may violate the Privacy Rule and result in penalties 
against the University as well as individual civil and criminal penalties against the Principal Investigator.  
 
 
INSTRUCTIONS TO RESEARCHERS 
FOR PREPARING THE RESEARCH AUTHORIZATION FORM 
 
 
1. Complete the first section of the Authorization form with title of the study, the OSU IRB protocol 
number, and PI name.  Add subject name at the time of authorization.  Do not include these 
instructions as part of the completed Authorization form. 
 
2. “Uses and Disclosures Covered by this Authorization” – List every known non-OSU person, class of 
persons, or organizations (including the sponsor agency or company, known subsidiaries of the 
sponsor, cooperative data groups, etc.) that may create, disclose, receive, and/or use the information 
in connection with the study.  Fill in the blanks on the form (and delete the instructions in italics as 
well as inapplicable bulleted sections) as appropriate.  If information will not be disclosed outside of 
The Ohio State University, delete all bullets and insert “None”.  Note: if a person(s) or organization is 
not listed on the form, they may not create, disclose, receive or use PHI in connection with the study. 
 
3a. “HIPAA Privacy Contact” – If the research involves the use of medical records from the University 
Health System, where applicable, insert the name and address of Margaret Johnson, HIPAA Privacy 
Manager, the Ohio State University Medical Center, 140 Doan Hall, 410 W. Tenth Avenue, 
Columbus, Ohio 43210.   
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 3b. If the research solely involves the use of personal health records at non-University Health System 
clinics or health care facilities (for example, the Dental School, Optometry School, Nisonger Center, 
Younkin Center, Psychological Services Center, Anxiety and Stress Disorder Clinic, Marriage & 
Family Therapy Clinic, Camera Center or faculty practice group such as OSU-P) insert the name and 
address of the appropriate Privacy Contact for the center, school, clinic or practice group.  If 
unknown, contact the director of the health center, school, clinic or practice group or the Office of 
Legal Affairs at (614) 292-0611 for the name and address of the applicable Privacy Contact.   
 
4. The Authorization must be presented to all newly enrolled or “re-consented” subjects in IRB-
approved research beginning April 14, 2003 at the time the IRB-approved consent form is signed.  
The subject or his/her legally authorized representative must be provided with a copy of this form 
after it has been signed.  The original, signed copy must be retained in the research file for a period of 
six years from the date the Authorization was signed (or longer, according to sponsor requirements).  
Prior IRB approval of the Authorization is not required; however, the Privacy Contact and/or HIPAA 
Privacy Board may conduct audits of the Authorization to ensure completeness.   
 
5a. “Notice of Privacy Practices” – Each subject who receives health care services at the 
University on or after April 14, 2003 should receive a copy of a Notice of Privacy Practices (NPP) and 
sign an acknowledgement (NPP Acknowledgement form) that (s)he obtained the NPP.   
 
5b. If the research involves the use of health and/or medical records from the University 
Health System and the subject has not received a copy of the University Health System’s NPP, provide 
the subject with a copy of the NPP.  The subject should sign a copy of the University Health System’s 
NPP Acknowledgement form.  The original, signed copy of the NPP Acknowledgement form must be 
retained in the research file for a period of six years from the date the NPP Acknowledgement was signed 
(or longer, according to sponsor requirements).  The University Health System’s NPP and NPP 
Acknowledgement form are available in electronic format on the Office of Responsible Research 
Practices (ORRP) website at http://www.orrp.ohio-state.edu/ as well as the Medical Center’s website at 
http://www.osumedcenter.edu. 
 
5c. If the research involves the use of health records at other non-University Health System 
clinics or facilities (including the sites listed above in item 3b.) and the subject has not received a copy of 
the facility or clinic’s individual NPP, provide the subject with a copy of the NPP.  Contact the director of 
the applicable health center, school, clinic or practice group to obtain a copy of the NPP and the NPP 
Acknowledgement form.  The original, signed copy of the NPP Acknowledgement form must be retained 
in the research file for a period of six years from the date the NPP Acknowledgement was signed (or 
longer, according to sponsor requirements).  
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THE OHIO STATE UNIVERSITY 
AUTHORIZATION TO USE 
PERSONAL HEALTH INFORMATION IN RESEARCH 
 
 
 
Title of the Study: Use of Nutritional Supplements and CAM (Complementary and Alternative 
Medicine) by Prostate and Breast Cancer Patients Undergoing Radiotherapy. 
 
OSU Protocol Number: 2002C0263 
 
Principal Investigator: Steven K. Clinton, MD. Ph.D. 
  
 
Subject Name__________________________________________________________ 
 
Before researchers use or share any health information about you as part of this study, The Ohio State 
University is required to obtain your authorization. This helps explain to you how this information will be 
used or shared with others involved in the study.   
 
• The Ohio State University and its hospitals, clinics, health-care providers and researchers are required 
to protect the privacy of your health information.   
• You should have received a Notice of Privacy Practices when you received health care services here.  
If not, let us know and a copy will be given to you.  Please carefully review this information. Ask if 
you have any questions or do not understand any parts of this notice. 
• If you agree to take part in this study your health information will be used and shared with others 
involved in this study. Also, any new health information about you that comes from tests or other 
parts of this study will be shared with those involved in this study. 
• Health information about you that will be used or shared with others involved in this study may 
include your research record and any health care records at the Ohio State University. For example, 
this may include your medical records, x-ray or laboratory results.  Psychotherapy notes in your 
health records (if any) will not, however, be shared or used. Use of these notes requires a separate, 
signed authorization. 
 
Please read the information carefully before signing this form. Please ask if you have any questions about 
this authorization, the University’s Notice of Privacy Practices or the study before signing this form. 
 
Initials/Date: _______________ 
 
Page 1 of 3 
Those Who May Use, Share And Receive Your Information As Part Of This Study 
 
• Researchers and staff at The Ohio State University will use, share and receive your personal health 
information for this research study. Other Ohio State University staff not involved in the study but 
who may become involved in your care for study-related treatment will have access to your 
information.  
• Those who oversee the study will have access to your information, including: 
• Members and staff of the Ohio State University’s Institutional Review Boards, including the 
Western Institutional Review Board 
• The Office for Responsible Research Practices  
• University data safety monitoring committees  
• The Ohio State University Research Foundation 
• Your health information may also be shared with federal and state agencies that have oversight of the 
study or to whom access is required under the law. These may include:  
• The Food and Drug Administration 
• The Office for Human Research Protections 
• The National Institutes of Health  
• The Ohio Department of Human Services  
 
These researchers, companies and/or organization(s) outside of The Ohio State University may also use, 
share and receive your health information in connection with this study: Not applicable 
 
 
The information that is shared with those listed above may no longer be protected by federal privacy 
rules. 
 
 Initials/Date______________ 
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Authorization Period 
 
This authorization will not expire unless you change your mind and revoke it in writing. There is no set 
date at which your information will be destroyed or no longer used.  This is because the information used 
and created during the study may be analyzed for many years, and it is not possible to know when this 
will be complete.   
 
Signing the Authorization 
 
• You have the right to refuse to sign this authorization.  Your health care outside of the study, payment 
for your health care, and your health care benefits will not be affected if you choose not to sign this 
form.  
• You will not be able to take part in this study and will not receive any study treatments if you do not 
sign this form. 
• If you sign this authorization, you may change your mind at any time. Researchers may continue to 
use information collected up until the time that you formally changed your mind.  If you change your 
mind, your authorization must be revoked in writing.  To revoke your authorization, please write to: 
Steven K. Clinton MD. Ph.D. at A434 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 
43210-1240. 
or call the HIPAA privacy officer at 614.293.4477. 
• Signing this authorization also means that you will not be able to see or copy your study-related 
information until the study is completed. This includes any portion of your medical records that 
describes study treatment.  
 
Contacts for Questions 
 
• If you have any questions relating to your privacy rights, please contact the HIPAA privacy officer at 
614.293 4477. 
• If you have any questions relating to the research, please contact Steven K. Clinton MD. Ph.D. at 614 
293 8396. 
 
Signature 
 
I have read (or someone has read to me) this form and have been able to ask questions. All of my 
questions about this form have been answered to my satisfaction.  By signing below, I permit Steven K. 
Clinton MD. Ph.D. and the others listed on this form to use and share my personal health information for 
this study.  I will be given a copy of this signed form. 
 
Signature________________________________________________________  
(Subject or Legally Authorized Representative) 
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Name _____________________________________________________________  
(Print name above) 
(If legal representative, also print relationship to subject.) 
 
Date___________ Time __________ AM / PM 
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